Disease: Pulmonary aspergilloma

Evaluating the Potential of Galactosaminogalactan as a Diagnostic Target for Invasive Aspergillosis

mycolabadmin

Researchers developed a new test to detect Aspergillus fungal infections using an antibody that recognizes a fungal component called GAG. The test worked very well in mouse studies, reliably detecting the fungus in blood and other body fluids. However, when tested with samples from infected patients, the test could not find GAG in the blood or other fluids, though it could see the fungus in lung tissue. This suggests either patients don’t produce enough GAG in their bloodstream, or something in human biology interferes with detection.

Read More »

Pulmonary Aspergilloma in a Non-adherent Systemic Lupus Erythematosus Patient Receiving Long-Term Immunosuppression: A Report of a Rare Case

mycolabadmin

A patient with systemic lupus erythematosus (SLE), a chronic autoimmune disease treated with long-term immune-suppressing medications, developed a serious fungal lung infection called pulmonary aspergilloma. Despite the complexity of managing multiple conditions and extensive bilateral lung involvement, the patient was successfully treated with prolonged voriconazole antifungal therapy rather than surgery, emphasizing the importance of early recognition and tailored treatment in immunocompromised patients.

Read More »

Evaluating the Potential of Galactosaminogalactan as a Diagnostic Target for Invasive Aspergillosis

mycolabadmin

Researchers developed a new test to detect invasive fungal infections caused by Aspergillus by targeting a molecule called galactosaminogalactan (GAG) on the fungus surface. The test worked very well in mice with the infection and showed better specificity than current methods. However, the test did not detect GAG in blood or other body fluids from human patients, suggesting that additional research is needed before it can be used clinically.

Read More »
Scroll to Top